The primary role of the Immune Reagents/Assay Core Facility is to provide cells antibodies and assays to the individual project components of the Program. The Core Facility is also involved in developing new assay technologies and new antibodies as well as serving as a central repository for blood and tissue samples collected during this project. In the last project, Core B was designated the Cell Biology Core and supplied antibodies, cells and assays to the investigators of the Program. In the current application, Core B is under new leadership and the technologies provided by the core are being expanded. Dr. Behnaz Parhami-Seren, Research Associate Professor of Biochemistry, is the Core Unit Leader in the current application. Dr. Parhami-Seren brings a wealth of experience in gene cloning, mutagenesis, production of cDNA libraries, phage display of protein and peptide libraries and expression of engineered antibodies and proteins in prokaryotic cells to the existing facility. Dr. Russell Tracy, Professor of Pathology and Associate Dean of Research, will continue to provide leadership in the realm of assay technologies and monoclonal antibody production. Dr. R. Tracy will serve as Co-Leader of the core facility. The Immune Reagents/Assay Core will thus provide investigators with a broad range of state-of-the-art technology and significant expertise to further enhance the many research opportunities available to the individual projects.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL046703-12
Application #
6657104
Study Section
Project Start
2002-09-01
Project End
2003-08-31
Budget Start
Budget End
Support Year
12
Fiscal Year
2002
Total Cost
$186,685
Indirect Cost
Name
University of Vermont & St Agric College
Department
Type
DUNS #
066811191
City
Burlington
State
VT
Country
United States
Zip Code
05405
Kusak, Piotr; Czarnecka, Danuta; Gissel, Matthew et al. (2016) Activated factor IX, factor XI and tissue factor identify patients with permanent atrial fibrillation treated with warfarin who are at risk of ischemic stroke. Arch Med Sci 12:1000-1007
Bouchard, Beth A; Chapin, John; Brummel-Ziedins, Kathleen E et al. (2015) Platelets and platelet-derived factor Va confer hemostatic competence in complete factor V deficiency. Blood 125:3647-50
Brummel-Ziedins, Kathleen E; Everse, Stephen J; Mann, Kenneth G et al. (2014) Modeling thrombin generation: plasma composition based approach. J Thromb Thrombolysis 37:32-44
Bouchard, Beth A; Gissel, Matthew T; Whelihan, Matthew F et al. (2014) Platelets do not express the oxidized or reduced forms of tissue factor. Biochim Biophys Acta 1840:1188-93
de Haan, Hugoline G; Bezemer, Irene D; Vossen, Carla Y et al. (2014) Genetic variants in Cell Adhesion Molecule 1 (CADM1): a validation study of a novel endothelial cell venous thrombosis risk factor. Thromb Res 134:1186-92
Undas, A; Brummel-Ziedins, K E; Mann, K G (2014) Anticoagulant effects of statins and their clinical implications. Thromb Haemost 111:392-400
Whelihan, Matthew F; Kiankhooy, Armin; Brummel-Ziedins, Kathleen E (2014) Thrombin generation and fibrin clot formation under hypothermic conditions: an in vitro evaluation of tissue factor initiated whole blood coagulation. J Crit Care 29:24-30
Brummel-Ziedins, Kathleen E; Lam, Phillip H; Gissel, Matthew et al. (2013) Depletion of systemic concentrations of coagulation factors in blood from patients with atherosclerotic vascular disease. Coron Artery Dis 24:468-74
Young, Guy; Sorensen, Benny; Dargaud, Yesim et al. (2013) Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. Blood 121:1944-50
Krudysz-Amblo, Jolanta; Jennings 2nd, Mark E; Knight, Tyler et al. (2013) Disulfide reduction abolishes tissue factor cofactor function. Biochim Biophys Acta 1830:3489-96

Showing the most recent 10 out of 247 publications